Japanese drugmakers reduce Russia business in wake of Ukraine war

They join global peers in pulling back as logistics, payment systems deteriorate

20220512 Daiichi Sankyo.jpg

Japan's Daiichi Sankyo has halted sales of some of its drugs to local distributors in Russia.

Nikkei staff writers

TOKYO -- Major Japanese pharmaceutical companies are reducing their business in Russia, joining their global peers in pulling back as the nation's invasion of Ukraine makes it tougher to operate there.

Daiichi Sankyo has halted sales of some of its drugs to local distributors in Russia, while Eiken Chemical has tentatively stopped supplying reagents used in blood tests for cancer.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.